FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2520044757> ?p ?o ?g. }

• W2520044757 endingPage "4656" @default.
• W2520044757 startingPage "4643" @default.
• W2520044757 abstract "Dual-function synthetic peptide derived from BMP4 for highly efficient tumor targeting and antiangiogenesis Suk Hyun Choi,1,* Jue Yeon Lee,2,* Jin Sook Suh,1 Yoon Shin Park,3 Chong Pyoung Chung,2 Yoon Jeong Park1 1Department of Dental Regenerative Biotechnology, Dental Research Institute, 2Central Research Institute, Nano Intelligent Biomedical Engineering Corporation (NIBEC), School of Dentistry, Seoul National University, Seoul, 3Department in Microbiology, School of Biological Sciences, College of Natural Sciences, Chungbuk National University, Cheongju, South Korea *These authors contributed equally to this work Abstract: Angiogenesis plays a critical role in the growth and metastasis of cancer, and growth factors released from cancer promote blood-vessel formation in the tumor microenvironment. The angiogenesis is accelerated via interactions of growth factors with the high-affinity receptors on cancer cells. In particular, heparan sulfate proteoglycans (HSPGs) on the surface of cancer cells have been shown to be important in many aspects of determining a tumor’s phenotype and development. Specifically, the regulation of the interactions between HSPGs and growth factors results in changes in tumor progression. A peptide with heparin-binding (HBP) activity has been developed and synthesized to inhibit tumor growth via the prevention of angiogenesis. We hypothesized that HBP could inhibit the interaction of growth factors and HSPGs on the surface of cancer cells, decrease paracrine signaling in endothelial cells (ECs), and finally decrease angiogenesis in the tumor microenvironment. In this study, we found that HBP had antiangiogenic effects in vitro and in vivo. The conditioned media obtained from a breast cancer cell line treated with HBP were used to culture human umbilical vein ECs (HUVECs) to evaluate the antiangiogenic effect of HBP on ECs. HBP effectively inhibited the migration, invasion, and tube formation of HUVECs in vitro. In addition, the expressions of angiogenesis-mediating factors, including ERK, FAK, and Akt, were considerably decreased. HBP also decreased the levels of invasive factors, including MMP2 and MMP9, secreted by the HUVECs. We demonstrated significant suppression of tumor growth in a breast cancer xenograft model and enhanced distribution of HBP at the site of tumors. Taken together, our results show that HBP has antiangiogenic effects on ECs, and suggest that it may serve as a potential antitumor agent through control of the tumor microenvironment. Keywords: heparin-binding peptide, HBP, antiangiogenesis, heparan sulfate proteoglycans, HSPGs, endothelial cells, breast cancer xenograft, tumor microenvironment" @default.
• W2520044757 created "2016-09-23" @default.
• W2520044757 creator A5000744257 @default.
• W2520044757 creator A5001868746 @default.
• W2520044757 creator A5013198280 @default.
• W2520044757 creator A5042663358 @default.
• W2520044757 creator A5087435615 @default.
• W2520044757 creator A5088097250 @default.
• W2520044757 date "2016-09-01" @default.
• W2520044757 modified "2023-09-28" @default.
• W2520044757 title "Dual-function synthetic peptide derived from BMP4 for highly efficient tumor targeting and antiangiogenesis" @default.
• W2520044757 cites W1483862258 @default.
• W2520044757 cites W1559400457 @default.
• W2520044757 cites W1584552481 @default.
• W2520044757 cites W1679229092 @default.
• W2520044757 cites W1813911660 @default.
• W2520044757 cites W1842385511 @default.
• W2520044757 cites W1912862036 @default.
• W2520044757 cites W1965144118 @default.
• W2520044757 cites W1965325738 @default.
• W2520044757 cites W1968744437 @default.
• W2520044757 cites W1969834700 @default.
• W2520044757 cites W1978837916 @default.
• W2520044757 cites W1979864237 @default.
• W2520044757 cites W1982423863 @default.
• W2520044757 cites W1982912692 @default.
• W2520044757 cites W1986222727 @default.
• W2520044757 cites W1996013670 @default.
• W2520044757 cites W2004596698 @default.
• W2520044757 cites W2008581828 @default.
• W2520044757 cites W2009120703 @default.
• W2520044757 cites W2018512891 @default.
• W2520044757 cites W2029176649 @default.
• W2520044757 cites W2033818437 @default.
• W2520044757 cites W2039212876 @default.
• W2520044757 cites W2040854254 @default.
• W2520044757 cites W2045983213 @default.
• W2520044757 cites W2054162382 @default.
• W2520044757 cites W2057234268 @default.
• W2520044757 cites W2064623632 @default.
• W2520044757 cites W2069640031 @default.
• W2520044757 cites W2087818844 @default.
• W2520044757 cites W2091774189 @default.
• W2520044757 cites W2092751827 @default.
• W2520044757 cites W2094393536 @default.
• W2520044757 cites W2106086622 @default.
• W2520044757 cites W2117188579 @default.
• W2520044757 cites W2119531959 @default.
• W2520044757 cites W2124399329 @default.
• W2520044757 cites W2136911306 @default.
• W2520044757 cites W2141046053 @default.
• W2520044757 cites W2150561062 @default.
• W2520044757 cites W2156713309 @default.
• W2520044757 cites W2162573695 @default.
• W2520044757 cites W2417725990 @default.
• W2520044757 cites W4249388929 @default.
• W2520044757 doi "https://doi.org/10.2147/ijn.s115044" @default.
• W2520044757 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5028098" @default.
• W2520044757 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27695323" @default.
• W2520044757 hasPublicationYear "2016" @default.
• W2520044757 type Work @default.
• W2520044757 sameAs 2520044757 @default.
• W2520044757 citedByCount "5" @default.
• W2520044757 countsByYear W25200447572017 @default.
• W2520044757 countsByYear W25200447572020 @default.
• W2520044757 countsByYear W25200447572021 @default.
• W2520044757 countsByYear W25200447572022 @default.
• W2520044757 crossrefType "journal-article" @default.
• W2520044757 hasAuthorship W2520044757A5000744257 @default.
• W2520044757 hasAuthorship W2520044757A5001868746 @default.
• W2520044757 hasAuthorship W2520044757A5013198280 @default.
• W2520044757 hasAuthorship W2520044757A5042663358 @default.
• W2520044757 hasAuthorship W2520044757A5087435615 @default.
• W2520044757 hasAuthorship W2520044757A5088097250 @default.
• W2520044757 hasBestOaLocation W25200447571 @default.
• W2520044757 hasConcept C121608353 @default.
• W2520044757 hasConcept C126322002 @default.
• W2520044757 hasConcept C150903083 @default.
• W2520044757 hasConcept C170493617 @default.
• W2520044757 hasConcept C185592680 @default.
• W2520044757 hasConcept C207001950 @default.
• W2520044757 hasConcept C2776107976 @default.
• W2520044757 hasConcept C2779013556 @default.
• W2520044757 hasConcept C2780394083 @default.
• W2520044757 hasConcept C3020616263 @default.
• W2520044757 hasConcept C502942594 @default.
• W2520044757 hasConcept C55493867 @default.
• W2520044757 hasConcept C71924100 @default.
• W2520044757 hasConcept C7876069 @default.
• W2520044757 hasConcept C86803240 @default.
• W2520044757 hasConcept C95444343 @default.
• W2520044757 hasConcept C96232424 @default.
• W2520044757 hasConceptScore W2520044757C121608353 @default.
• W2520044757 hasConceptScore W2520044757C126322002 @default.
• W2520044757 hasConceptScore W2520044757C150903083 @default.
• W2520044757 hasConceptScore W2520044757C170493617 @default.
• W2520044757 hasConceptScore W2520044757C185592680 @default.
• W2520044757 hasConceptScore W2520044757C207001950 @default.

• next